Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Bromus Inermis Pollen is a non-standardized allergenic extract used primarily for the diagnosis and treatment of grass pollen-induced allergic rhinitis and asthma. It belongs to the class of non-standardized pollen allergenic extracts.
Name
Bromus Inermis Pollen
Raw Name
BROMUS INERMIS POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
19
Variant Count
20
Last Verified
February 17, 2026
About Bromus Inermis Pollen
Bromus Inermis Pollen is a non-standardized allergenic extract used primarily for the diagnosis and treatment of grass pollen-induced allergic rhinitis and asthma. It belongs to the class of non-standardized pollen allergenic extracts.
Detailed information about Bromus Inermis Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Bromus Inermis Pollen.
Bromus Inermis Pollen, commonly known as Smooth Brome grass pollen, is a biological substance utilized in the field of clinical allergy and immunology. It belongs to a class of drugs known as Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are derived from the pollen of the Bromus inermis plant, a perennial cool-season grass widely distributed across North America, Europe, and Northern Asia. In clinical practice, this extract is employed for two primary purposes: the diagnostic identification of specific IgE-mediated hypersensitivity (Type I allergy) and as a therapeutic agent in allergen-specific immunotherapy (SIT), often referred to as 'allergy shots.'
Pharmacologically, Bromus Inermis Pollen is classified as a non-standardized extract because its potency is not measured by a federally mandated bioequivalent allergy unit (BAU), but rather by weight/volume (w/v) or Protein Nitrogen Units (PNU). The FDA has historically permitted the use of these extracts based on their long-standing clinical utility in identifying patients with seasonal allergic rhinitis (hay fever) and allergic conjunctivitis. Healthcare providers typically use this extract when a patient exhibits symptoms such as sneezing, nasal congestion, and itchy eyes during the late spring and early summer months when brome grass typically pollinates.
The mechanism of action for Bromus Inermis Pollen differs significantly depending on whether it is used for diagnosis or treatment. At the molecular level, the extract contains various proteins (allergens) that are recognized by the immune systems of sensitized individuals.
Diagnostic Mechanism: When applied via a skin prick test (percutaneous) or intradermal injection, the allergens in the extract cross-link specific IgE antibodies bound to the surface of mast cells in the skin. This cross-linking triggers mast cell degranulation, releasing inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This results in a localized 'wheal and flare' reaction (a raised bump surrounded by redness), which confirms that the patient is sensitized to Smooth Brome grass.
Therapeutic Mechanism (Immunotherapy): When used in immunotherapy, the goal is to induce 'immune tolerance.' This is a complex process involving several immunological shifts. Initially, the repeated administration of increasing doses of the allergen leads to the production of 'blocking antibodies,' specifically IgG4. These antibodies compete with IgE for allergen binding, thereby preventing the allergic cascade. Furthermore, immunotherapy promotes a shift in the T-cell response from a Th2-dominated profile (which promotes allergy) to a Th1-dominated profile. It also induces the production of regulatory T-cells (Tregs) that secrete anti-inflammatory cytokines like Interleukin-10 (IL-10) and Transforming Growth Factor-beta (TGF-β), which suppress the allergic inflammation in the respiratory mucosa.
Unlike traditional small-molecule drugs, the pharmacokinetics of allergenic extracts like Bromus Inermis Pollen are not characterized by traditional absorption, distribution, metabolism, and excretion (ADME) studies. Because these are complex mixtures of proteins administered locally (into the skin or subcutaneous tissue), their 'movement' through the body is unique.
Bromus Inermis Pollen is FDA-indicated for the following uses:
Off-label uses are rare, though some clinicians may use these extracts in experimental sublingual immunotherapy (SLIT) protocols, although standardized tablets are generally preferred for that route.
Bromus Inermis Pollen is available in several specialized formulations for clinical use:
> Important: Only your healthcare provider can determine if Bromus Inermis Pollen is right for your specific condition. The selection of the appropriate concentration and administration route requires expert clinical judgment by an allergist or immunologist.
Dosage for Bromus Inermis Pollen is highly individualized and is never a 'one-size-fits-all' approach. The dosage is measured in Protein Nitrogen Units (PNU) or weight/volume (w/v) dilutions.
Immunotherapy consists of two distinct phases:
Bromus Inermis Pollen is generally considered safe for use in children, though the decision to start immunotherapy in very young children (under age 5) is made cautiously. The dosage logic for children is identical to that for adults, as the dose is based on the individual's level of sensitivity rather than body weight. However, healthcare providers may use a more conservative build-up schedule for pediatric patients to minimize the risk of systemic reactions.
No dosage adjustments are typically required for patients with renal impairment, as the allergens are proteins degraded by proteases rather than cleared by the kidneys.
No dosage adjustments are required for patients with hepatic impairment.
Elderly patients (over 65) may have a higher prevalence of underlying cardiovascular disease. Because the treatment for a severe allergic reaction (epinephrine) can be hard on the heart, healthcare providers may use lower doses or slower build-up schedules in this population.
Bromus Inermis Pollen extracts MUST be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.
If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed:
An overdose in the context of allergenic extracts refers to receiving a dose higher than the patient's current tolerance level.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Never attempt to self-administer these injections at home.
Side effects from Bromus Inermis Pollen are very common, particularly during the build-up phase of immunotherapy. Most are localized to the site of administration.
> Warning: Stop taking Bromus Inermis Pollen and call your doctor immediately if you experience any of these symptoms. These may indicate the onset of anaphylaxis, a life-threatening allergic reaction.
There are no known long-term 'toxic' side effects associated with the use of Bromus Inermis Pollen extracts. Unlike many medications, these are biological proteins that do not accumulate in organs. The long-term 'effect' is intended to be beneficial—a permanent or semi-permanent reduction in allergy symptoms. However, if a patient is over-treated for many years without benefit, they may remain at a persistent risk for acute systemic reactions during each administration.
Allergenic extracts, including Bromus Inermis Pollen, carry an FDA-mandated warning regarding the risk of severe systemic reactions.
Report any unusual symptoms to your healthcare provider. Even a large local reaction (larger than a half-dollar) should be reported, as it may be a precursor to a systemic reaction at the next dose.
Bromus Inermis Pollen is a potent biological agent. Its use is restricted to diagnostic and therapeutic protocols supervised by specialists. Patients must be aware that while the goal is to reduce allergy symptoms, the treatment itself involves exposing the body to the very substance that causes the allergy, which inherently carries risk.
No FDA black box warnings specifically for 'Bromus Inermis Pollen' as a standalone entity, but it falls under the class-wide black box warning for all Allergenic Extracts. The warning states: 'This product can cause severe systemic reactions, including anaphylaxis, which may be fatal. Patients should be informed of the risks and monitored for at least 30 minutes. Patients with unstable asthma or those taking beta-blockers are at increased risk for complications.'
Bromus Inermis Pollen does not typically cause drowsiness. However, if a patient experiences a systemic reaction or receives epinephrine to treat a reaction, they may feel shaky, anxious, or lightheaded. It is generally safe to drive to and from appointments unless a reaction occurs.
There is no direct interaction between alcohol and Bromus Inermis Pollen. However, alcohol can cause vasodilation (opening of blood vessels), which could theoretically speed up the absorption of the allergen. It is best to avoid heavy alcohol consumption on the day of an injection.
Immunotherapy is typically a 3-to-5-year commitment. Stopping the treatment early will not cause 'withdrawal,' but the allergy symptoms are likely to return. If you must stop, no tapering is required; however, you should discuss the reasons for discontinuation with your allergist.
> Important: Discuss all your medical conditions with your healthcare provider before starting Bromus Inermis Pollen. Be sure to mention any history of heart disease or severe asthma.
While there are few 'drug-drug' interactions in the traditional sense, certain medications make the use of Bromus Inermis Pollen extremely dangerous.
There are no known direct food interactions with Bromus Inermis Pollen. However, patients with 'Oral Allergy Syndrome' (OAS) may find that eating certain fruits or vegetables (like melons or tomatoes) during the brome grass season increases their overall 'allergic load,' potentially making them more sensitive to their injections.
For each major interaction, the primary concern is either the masking of diagnostic results or the interference with emergency treatment (epinephrine). The clinical consequence of the latter is increased mortality risk during an adverse event.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure, heart rhythm, or depression.
Conditions where Bromus Inermis Pollen must NEVER be used include:
Conditions requiring careful risk-benefit analysis by a specialist:
Bromus Inermis is a member of the Poaceae family. Patients allergic to Smooth Brome grass are very likely to show cross-sensitivity to other 'cool-season' grasses, such as:
> Important: Your healthcare provider will evaluate your complete medical history and current health status before prescribing Bromus Inermis Pollen extracts.
Bromus Inermis Pollen is classified by the FDA in Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.
It is not known whether the protein components of Bromus Inermis Pollen are excreted in human milk. However, because these are large proteins that are digested in the infant's stomach, the risk to a nursing infant is considered extremely low. Immunotherapy is generally considered safe for breastfeeding mothers.
There are no specific studies on Bromus Inermis Pollen in patients with kidney disease. However, based on the pharmacology of protein extracts, no dosage adjustment is required. The primary concern would be the patient's overall ability to handle the physiological stress of a potential systemic reaction.
Liver disease does not affect the metabolism of allergenic extracts. No dosage adjustments are necessary for patients with hepatic impairment.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you are pregnant, planning to become pregnant, or have underlying heart or kidney conditions.
Bromus Inermis Pollen acts as an immunomodulator. In a sensitized individual, the 'natural' response to brome grass pollen is the production of IgE antibodies by B-cells. These IgE antibodies coat mast cells and basophils. Upon re-exposure, the pollen proteins cross-link the IgE, causing a massive release of inflammatory chemicals.
Allergen-specific immunotherapy (AIT) with Bromus Inermis Pollen works by reversing this process. By introducing the allergen in small, controlled doses via the subcutaneous route, the immune system is forced to process the allergen in a non-inflammatory context. This leads to:
| Parameter | Value |
|---|---|
| Bioavailability | Low (systemically); High (locally in skin/lymph nodes) |
| Protein Binding | N/A (Proteins are the active agent) |
| Half-life | Hours (local degradation) |
| Tmax | 1-2 hours (for systemic absorption of small fractions) |
| Metabolism | Proteolytic degradation by cellular proteases |
| Excretion | Minimal renal excretion of small peptides |
Bromus Inermis Pollen extract is a complex biological mixture. It contains multiple allergenic proteins, typically ranging in molecular weight from 10 to 70 kDa. The most significant allergens in brome grass are likely homologous to the 'Group 1' and 'Group 5' allergens found in other grasses (e.g., Bro i 1). The extract is typically standardized by Protein Nitrogen Units (PNU), where 1 mg of protein nitrogen equals 100,000 PNU.
Bromus Inermis Pollen is a member of the Non-Standardized Pollen Allergenic Extract class. It is grouped with other grass extracts like Timothy, Orchard, and June grass. Unlike 'Standardized' extracts (which have a Bioequivalent Allergy Unit or BAU rating), non-standardized extracts rely on weight/volume or PNU for dosing consistency.
Common questions about Bromus Inermis Pollen
Bromus Inermis Pollen extract is primarily used for the diagnosis and treatment of seasonal allergies caused by Smooth Brome grass. In the diagnostic phase, it is used in skin prick tests to confirm if a patient is allergic to this specific grass. In the therapeutic phase, it is used in allergen-specific immunotherapy, commonly known as allergy shots. This treatment involves giving gradually increasing doses of the pollen to help the patient's immune system build up a tolerance. Over time, this can significantly reduce symptoms like sneezing, itchy eyes, and asthma flares during the grass pollen season.
The most frequent side effects are localized to the site of the injection. Most patients experience redness, itching, and a small amount of swelling at the injection site, similar to a mosquito bite. These reactions usually appear within minutes and fade within a few hours. Some patients may also experience 'late-phase' reactions, where the arm becomes swollen and warm several hours later. While less common, systemic symptoms like mild hay fever or tiredness on the day of the injection can also occur.
There is no direct chemical interaction between alcohol and Bromus Inermis Pollen extracts. However, healthcare providers generally recommend avoiding heavy alcohol consumption on the day of an allergy injection. Alcohol causes blood vessels to dilate (expand), which could potentially increase the speed at which the allergen is absorbed into your bloodstream. This might slightly increase the risk of a systemic allergic reaction. Additionally, alcohol can mask the early symptoms of an allergic reaction, making it harder for you to recognize if you need medical help.
The use of Bromus Inermis Pollen during pregnancy is handled with extreme caution. While it is not known to be directly toxic to the fetus, a severe allergic reaction (anaphylaxis) in the mother can be very dangerous for the baby due to a sudden drop in oxygen levels. Generally, doctors will not start a new immunotherapy program for a pregnant woman. However, if a woman is already on a stable 'maintenance dose' and becomes pregnant, the doctor may choose to continue the treatment at that same dose, as the risk of a reaction is lower once the body has already adjusted to the extract.
Immunotherapy with Bromus Inermis Pollen is a long-term treatment and does not provide immediate relief like an antihistamine would. Most patients begin to notice a reduction in their allergy symptoms after 3 to 6 months of consistent treatment, usually once they reach the higher doses in the 'build-up' phase. Significant improvement is typically seen after the first full year of treatment. For the best long-term results and to potentially achieve permanent relief, most specialists recommend continuing the injections for a total of 3 to 5 years.
Yes, you can stop taking Bromus Inermis Pollen injections at any time without experiencing physical withdrawal symptoms. However, because immunotherapy works by gradually retraining your immune system, stopping the treatment prematurely—especially in the first year or two—usually means that your allergy symptoms will eventually return to their original severity. If you are considering stopping because of side effects or scheduling issues, you should discuss this with your allergist first, as they may be able to adjust your dose or schedule.
If you miss a dose, you should contact your allergist's office to reschedule as soon as possible. Do not try to 'double up' on your next dose. If you have only missed one week, your doctor may give you your regular scheduled dose. However, if you have missed several weeks, your immune system's tolerance may have dropped slightly. In these cases, the doctor will usually reduce your dose for one or more sessions to ensure you don't have a reaction, and then gradually build you back up to your previous level.
There is no clinical evidence to suggest that Bromus Inermis Pollen extracts cause weight gain. These extracts consist of small amounts of natural proteins that are processed by the immune system and do not affect the body's metabolism, appetite, or fat storage. If you experience weight gain while on immunotherapy, it is likely due to other factors, such as the use of oral corticosteroids for asthma or other unrelated lifestyle changes. Always discuss unexpected weight changes with your primary care physician.
Most medications, such as birth control, cholesterol drugs, and antibiotics, do not interact with Bromus Inermis Pollen. However, heart and blood pressure medications called beta-blockers are a major concern because they can make an allergic reaction much harder to treat. Additionally, you must stop taking antihistamines several days before being tested with the pollen extract, as they will block the skin's reaction and lead to an inaccurate diagnosis. Always provide your allergist with a full list of your current medications.
The concept of 'generic' vs. 'brand name' is different for allergenic extracts than for pills. Bromus Inermis Pollen is produced by several different biological laboratories (such as ALK, Greer, or HollisterStier). While the extracts are essentially the same product—pollen from the same grass species—they are not considered identical because the manufacturing and concentration methods (PNU vs. w/v) can vary between companies. Your allergist will typically stick with one manufacturer for your entire course of treatment to ensure the dose remains consistent.